Frequencies and Association of CYP3A5 Polymorphism With Tacrolimus Concentration Among Renal Transplant Recipients in Vietnam

被引:6
作者
Xuan, Nguyen Thanh [1 ]
Hop, Vu Quang [2 ]
Kien, Truong Quy [3 ]
Toan, Pham Quoc [3 ]
Thang, Le Viet [3 ]
Binh, Ha Thanh [3 ]
Van Tran, Pham [2 ]
Minh, Hoang Thi [2 ]
Man, Pham Thi [4 ]
Cuong, Hoang Xuan [5 ]
Ben, Nguyen Huu [5 ]
Phuong, Nguyen Minh [5 ]
Linh, Nguyen Tung [5 ]
Linh, Nguyen Thuy [6 ,7 ]
Dung, Vu Dinh [6 ]
Quyen, Le Thi Bao [8 ]
Hang, Dinh Thi Thu [8 ]
Su, Hoang Xuan [8 ,9 ]
机构
[1] Vietnam Mil Med Univ, Mil Hosp 103, Dept Internal Med, Hanoi, Vietnam
[2] Vietnam Mil Med Univ, Mil Hosp 103, Dept Clin Biochem, Hanoi, Vietnam
[3] Vietnam Mil Med Univ, Mil Hosp 103, Dept Nephrol & Dialysis, Hanoi, Vietnam
[4] Natl Hosp Dermatol & Venereol, Dept Pharm, Hanoi, Vietnam
[5] Vietnam Mil Med Univ, Dept Occupat Med, Hanoi, Vietnam
[6] Vietnam Mil Med Univ, Inst Biomed & Pharm, Hanoi, Vietnam
[7] Natl Univ Hanoi, Fac Biol, Hanoi, Vietnam
[8] Hanoi Univ Sci & Technol, Hanoi, Vietnam
[9] Vietnam Mil Med Univ, Inst Biomed & Pharm, 222 Phung Hung str, Hanoi 100000, Vietnam
关键词
GENETIC-POLYMORPHISM; PHARMACOKINETICS; GENOTYPE;
D O I
10.1016/j.transproceed.2022.07.009
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. This study aims to investigate the frequencies and association of CYP3A5 poly-morphism with tacrolimus concentration among renal transplant recipients in Vietnam. Methods. Sixty-eight kidney transplant recipients were included in this study from the department of nephrology and dialysis, Military Hospital 103. Blood samples were collected for monitoring of tacrolimus levels and determination of CYP3A5 genetic polymorphism.Results. A total of 68 patients studied. The CYP3A5*3*3, CYP3A5*1*3, and CYP3A5*1*1 genotypes were detected in 48 (70.6%), 16 (23.5%), and 4 (5.9%), respectively. Tacrolimus con-centrations were much lower in CYP3A5 expressors than in CYP3A5 nonexpressors on the first day, month 1, 3, 6, and 12 (5.98 +/- 1.05 vs 6.57 +/- 1.03,P= .03; 5.79 +/- 1.13 vs 6.82 +/- 1.05, P < .001; 4.76 +/- 1.48 vs 6.73 +/- 1.09, P < .001; 4.29 +/- 1.64 vs 6.46 +/- 1.23, P < .001; 4.20 +/- 1.36 vs 6.04 +/- 1.26, P < .001), respectively. Notably, the concentration/dose ratio in the CYP3A5 expressors was lower than in CYP3A5 nonexpressors at time points of follow up (P < .001). However, there were no significant differences in the age, sex, HLA mismatch, type of donors, acute rejection, and creatinine levels at time points between group of CYP3A5 expres-sors and those of CYP3A5 nonexpressors.Conclusion. In conclusion, this research indicated the significant association of CYP3A5 genetic polymorphism with daily dose and tacrolimus concentrations in renal transplant recipi-ents. This study provided a closer step to individualize the dose of tacrolimus in renal transplant patients in Vietnam.
引用
收藏
页码:2140 / 2146
页数:7
相关论文
共 50 条
[41]   Influence of CYP3A5 and ABCB1 Polymorphism on Tacrolimus Drug Dosing in South Indian Renal Allograft Recipients [J].
Fernando, M. Edwin ;
Sellappan, Manokaran ;
Prasad, N. D. Srinivasa ;
Suren, Sujit ;
Thirumalvalavan, K. .
INDIAN JOURNAL OF NEPHROLOGY, 2019, 29 (04) :261-266
[42]   Effects of CYP3A5 polymorphism and the tacrolimus 12 h concentration on tacrolimus-induced acute renal dysfunction in patients with lupus nephritis [J].
Niioka, Takenori ;
Komatsuda, Atsushi ;
Kato, Shotaro ;
Togashi, Masaru ;
Okuyama, Shin ;
Omokawa, Ayumi ;
Nara, Mizuho ;
Wakui, Hideki ;
Takahashi, Naoto ;
Miura, Masatomo .
XENOBIOTICA, 2015, 45 (12) :1147-1153
[43]   Association between renal function and CYP3A5 genotype in heart transplant recipients treated with calcineurin inhibitors [J].
de Denus, Simon ;
Zakrzewski, Marcin ;
Barhdadi, Amina ;
Leblanc, Marie-Helene ;
Racine, Normand ;
Belanger, Francois ;
Carrier, Michel ;
Ducharme, Anique ;
Dube, Marie-Pierre ;
Turgeon, Jacques ;
White, Michel .
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2011, 30 (03) :326-331
[44]   Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients [J].
Tsuchiya, N ;
Satoh, S ;
Tada, H ;
Li, ZH ;
Ohyama, C ;
Sato, K ;
Suzuki, T ;
Habuchi, T ;
Kato, T .
TRANSPLANTATION, 2004, 78 (08) :1182-1187
[45]   Impact of CYP3A5 genotype on tacrolimus versus midazolam clearance in renal transplant recipients: new insights in CYP3A5-mediated drug metabolism [J].
de Jonge, Hylke ;
de Loor, Henriette ;
Verbeke, Krisitin ;
Vanrenterghem, Yves ;
Kuypers, Dirk R. J. .
PHARMACOGENOMICS, 2013, 14 (12) :1467-1480
[46]   CYP3A5 Polymorphism Effect on Cyclosporine Pharmacokinetics in Living Donor Renal Transplant Recipients: Analysis by Population Pharmacokinetics [J].
Song, Joohan ;
Kim, Myeong Gyu ;
Choi, Boyoon ;
Han, Na Young ;
Yun, Hwi-Yeol ;
Yoon, Jeong-Hyun ;
Oh, Jung Mi .
ANNALS OF PHARMACOTHERAPY, 2012, 46 (09) :1141-1151
[47]   Effect of CYP3A5 gene polymorphisms on tacrolimus concentration/dosage ratio in adult liver transplant patients [J].
Wang, L. ;
Liu, L. H. ;
Tong, W. H. ;
Wang, M. X. ;
Lu, S. C. .
GENETICS AND MOLECULAR RESEARCH, 2015, 14 (04) :15148-15157
[48]   Influence of CYP3A5 genetic polymorphism on cyclosporine A metabo-lism and elimination in Chinese renal transplant recipients [J].
Xiaoman CHU Haiping HAOGuangji WANG Lianqing GUO Peiqing MIN Department of Clinical PharmacologyGeneral Hospital of Nanjing Military AreaNanjing China Key Laboratory of Drug Metabolism and PharmacokineticsChina Pharmaceutical UniversityNanjing China .
ActaPharmacologicaSinica, 2006, (11) :1504-1508
[49]   Association Between CYP3A5 Genetic Polymorphisms with Tacrolimus Dose Requirement and Allograft Outcomes in Iranian Kidney Transplant Recipients [J].
Ghafari, Somayeh ;
Dashti-Khavidaki, Simin ;
Khatami, Mohammadreza ;
Ghahremani, Mohammad-Hossein ;
Seyednejad, Seyed-Afshin ;
Beh-Pajooh, Abbas .
IRANIAN JOURNAL OF KIDNEY DISEASES, 2019, 13 (06) :404-413
[50]   Effect of the CYP3A5 6986A&gt;G Polymorphism on Tacrolimus Pharmacokinetics in Liver Transplant Recipients: A Meta-analysis [J].
Buendia, J. A. ;
Bramuglia, G. ;
Staatz, C. E. .
THERAPEUTIC DRUG MONITORING, 2013, 35 (05) :657-657